September 23rd, 2021

Jointly creating the future of cell & gene therapy orchestration

Our first open X-CELLerator community event took place on September 23rd, 2021. We want to thank all of you for your participation and contribution to make this event outstanding and successul.

Furthermore, our experts would like to give an answer to the questions that have not been answered during the Q&A session.

In an Industry full of "(fast) followers": how to motivate manufacturers to join forces in order to work together?

From our point of view manufacturers and their therapies will only be successful if they join forces and aim for industry standards. They need to strive to reduce boundaries and establish a collaborative culture. Employees in hospitals, apheresis centers, labs etc. need to have the possibility to increase their efficiency in order to serve more patients in the next years. Therefore, a harmonized team full of experts is required to ensure scalability. End the end, manufactures will not compete on their individual supply chain setup – they will differentiate based on their therapy and its success. 

------------------

When the throughput of patient batches increases as companies advance in their clinical trials and commercial journey, is this approach of having people "check each shipment from end to end sustainable?

People checking each individual shipment manually from end-to-end will not be sufficient and sustainable in the long-run. However, in the first step we must ensure that no failures occur when a therapy is delivered to a patient. As numbers of therapies and patients are currently still low, we can make use of this situation in order to learn and steadily optimize processes and (IT) infrastrucutre. In the long-term, we need experts who oversee thousand of shipments of different manufactures in a kind of ‘control tower’ and who only interact in case of unforeseen circumstances. Our approach is to increase process efficiency, quality and safety with the combinational use of data, automation and humans.

September 23rd, 2021

Agenda

Download now

Speeches

By clicking on "Show content from YouTube.com", you give your consent for YouTube to set cookies on your device, which may also be used to analyze your usage behavior. You can revoke your consent at any time here.

Vision for the future eco-system for personalized medicine

Prof. Lutz Uharek
Expert Cell and Gene Therapies,
CEO and Founder Xencura GmbH

By clicking on "Show content from YouTube.com", you give your consent for YouTube to set cookies on your device, which may also be used to analyze your usage behavior. You can revoke your consent at any time here.

Supply Chain Challenges arising from new therapies

Christian Wolf
Executive Vice President Healthcare,
Arvato Supply Chain Solutions

By clicking on "Show content from YouTube.com", you give your consent for YouTube to set cookies on your device, which may also be used to analyze your usage behavior. You can revoke your consent at any time here.

Orchestrating Advanced Therapies: Concepts and Technical Ideas

Andreas Göbel
Managing Director,
Hypertrust Patient Data Care

By clicking on "Show content from YouTube.com", you give your consent for YouTube to set cookies on your device, which may also be used to analyze your usage behavior. You can revoke your consent at any time here.

Customer Example – Point of Care Production

Tol Trimborn
Chief Executive Officer,
Cellpoint

Presentations

Prof. Lutz Uharek

Vision for the future eco-system for personalized medicine

Christian Wolf

Supply Chain Challenges arising from new therapies

Dr. Andrea Zobel

Transportation – What it means to be one point globally

Andreas Göbel

Orchestrating Advanced Therapies: Concepts and Technical Ideas

Impressions behind the scenes